Role of Immunoglobulin Therapy to Prevent and Treat Infections

Aspasia Katragkou, Emmanuel Roilides, and Thomas J. Walsh

Immunoglobulin Use in Therapeutics and Historical Overview

Immunoglobulin therapy has been used for the prevention and treatment of infectious disease before the introduction of antimicrobial agents into the clinical practice. In the early 1890s, Emil von Behring and Shibasaburo Kitasato set the basis of “serum therapy” showing that antibody preparations derived from the serum of immunized animals have the ability to protect against bacterial toxins [115]. Ehrlich’s subsequent work contributed to the conception of passive immunity, demonstrating that increasing doses of bacterial toxins could provide immunity against lethal doses of toxin [68]. Cenci first used human serum in 1907 for the prevention of measles and thereafter for the prevention of pertussis and mumps [45]. Systemic administration of “serum therapy” was widely used in the 1930s for the treatment of bacterial and viral infections; however, its use was often associated with adverse reactions due to administration of large amounts of animal proteins, ranging from fever and chills to “serum sickness,” a form of immune complex disease, characterized by rash, proteinuria, and arthralgias [45]. After improvements in antibody purification methods, which reduced serum toxicity, the role of “serum therapy” was further expanded. In the pre-antibiotic era, serum therapy significantly reduced the mortality in some infectious outbreaks such as meningococcal and Haemophilus influenzae meningitis, pneumococcal pneumonia, and diphtheria. The efficacy of serum therapy varied with the type and severity of the infections and the timing of treatment administration in relation to symptom onset [27, 28, 43]. For some infections like whooping cough, anthrax, dysentery (Shigella dysenteriae), and gas gangrene, the efficacy of “serum therapy” was uncertain, while for other pathogens like Staphylococcus, Mycobacterium, and...
Salmonella species, no consistently effective sera were produced [28].

With the discovery of antibiotics in 1940s, the interest in “serum therapy” for the treatment of infectious disease waned. The initial interest in using combination therapies with antibiotics and serum was abandoned, as the potential benefits were marginal. Antimicrobial chemotherapy proved to be less toxic and more effective than serum therapy in the treatment of infections. However, Dr. Cohn’s discovery of purified antibodies through cold ethanol fractionation of plasma during the Second World War revived the interest in antibody treatment especially for infections not able to be treated with antibiotics. The fractionation procedure stabilizes the product, denatures most viruses, and assures a more uniform antibody content. Cohn fraction (IgG from plasma after cold alcohol fractionation) was initially used for prophylaxis against prevalent and life-threatening infections, such as measles.

It was not until 1952 that Bruton reported for the first time the use of immunoglobulin preparation injected subcutaneously for the treatment of a young boy with agammaglobulinemia [21]. Thereafter, the use of immunoglobulin injected intramuscularly became established as the standard therapy for primary immunodeficiencies, lasting until the development of purer and safer intravenous immunoglobulin preparation in the early 1980s [86].

The advent of hybridoma technology, which allows continuous generation of large quantities of monoclonal antibodies specific to antigens of interest and the generation of humanized antibodies, revolutionized antibody therapeutics [63]. Monoclonal antibody technology offers supply advantage, reduces the risks of adverse events, and decreases lot-to-lot variation. In the mid-1980s a monoclonal antibody (mAb) to CD3 was introduced into clinical practice to prevent organ rejection. Almost a decade later, the humanized mAb palivizumab (Synagis®, a humanized mouse monoclonal antibody to prevent RSV pulmonary infections in high-risk patients, especially infants) was licensed. Palivizumab was 50-fold more potent than the polyclonal product, resulting in reduced volume of administration and intramuscular use [45].

During the last three decades, 30 therapeutic mAbs have been licensed, mainly for treatment of malignancies and rheumatic or autoimmune diseases, but only two were licensed for infectious diseases (palivizumab and raxibacumab: human mAb to anthrax toxin). Although the use of mAbs to treat infectious diseases does not depend on discrimination between self-antigen as there are large antigenic differences between the microorganism and the host, the pace of discovery and development of new mAbs against infectious disease is limited. Currently, the areas of mAbs development have been focused on viral diseases without available vaccines [HIV, Ebola, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome, Marburg virus], viral disease with limited effective antiviral drugs (influenza, rabies), and bacterial toxin-mediated disease (anthrax, Clostridium difficile colitis). In the clinical setting, therapeutic mAbs can be used when there are nosocomial/iatrogenic outbreaks. For example, a new approach to the prevention of recurrent C. difficile infection is the administration of mAbs against C. difficile toxins (in addition to antibiotic therapy) as a form of passive immunity. Actoxumab and bezlotoxumab are fully human monoclonal antibodies that bind and neutralize C. difficile toxins A and B, respectively. A double-blind randomized placebo-controlled phase 3 trial showed that a single intravenous dose of bezlotoxumab when given with standard-of-care antibiotics provided protection against recurrent C. difficile infection for up to 12 weeks that was superior to that provided by treatment with standard-of-care antibiotics alone [114]. Other therapeutic mAbs can be applied in drug resistance (Staphylococcus aureus, VRSA), pandemic outbreaks (Ebola virus), bioterrorism attacks (Bacillus anthracis), emerging infectious diseases (Nipah anthracis), and use in high-risk host groups or in severe diseases (respiratory syncytial virus, cytomegalovirus retinitis in HIV patients, hepatitis C virus, influenza virus). Another application of therapeutic mAbs concerns their use as adjunct therapies that have anti-inflammatory or immune
modulatory roles (mAbs against TNF-α and other immune mediators) [45, 55].

**Immunoglobulins: Types and Characteristics**

Immunoglobulins are glycoprotein molecules that are produced by plasma cells in response to antigens or immunogens and which function as antibodies. Serum contains a heterogeneous immunoglobulin pool that reflects the host response to endogenous microbiota and the immunological memory of the host for a variety of acquired microbial agents [26]. Different immunoglobulins can differ structurally; however, they are built from the same basic units.

There are five classes of immunoglobulin, classified according to the type of heavy chain they possess (Table 17.1) [70]. Each class of immunoglobulins has a specific function, and deficiency of each class leads to particular dysfunction of immune system. Serum IgM predominates in the acute immune response to most antigens and is the most efficient complement-fixing immunoglobulin. Immunoglobulin class switching subsequently occurs, leading to a predominance of IgG, which is responsible for protection during the first infectious attack and long-term protection via memory B cells. Secretory IgA, due to its abundance in mucosal secretions, provides primary defense mechanism against some mucosal infections. IgE primarily defends against parasitic invasion [2].

Immunoglobulins together with T cells are the key mediators of adaptive immunity, and deficiencies in either of these two arms of the adaptive immune system can result in higher host susceptibility to bacterial, fungal, or viral infections [76]. Immunoglobulins interact with the

| Table 17.1 Properties of human serum immunoglobulin isotypes |
|---------------------------------------------------------------|
|                  | IgG | IgG1 | IgG2 | IgG3 | IgG4 | IgA | IgM | IgE | IgD |
| Molecular weight (x1000) |     | 146  | 146  | 170  | 146  | 320 | 900 | 73  | 70  |
| Heavy chain       |     | γ1   | γ2   | γ3   | γ4   | α   | μ   | ε   | δ   |
| In vivo serum half-life (days) |     | 21–23| 20–23| 7–8  | 21–23| 6   | 5   | 2.5 | 3   |
| Percent of total Ig |     | 66%  | 23%  | 7%   | 4%   | 13% | 6%  | 0.02%| 0.2%|
| Activate classical complement pathway |     | +    | +/− | ++ | − | − | +++ | − | − |
| Crosses placenta  |     | +    | +/− | +  | − | − | −   | − | − |
| Present on membrane of mature B cells |     | −    | − | − | − | + | − | − | + |
| Bind to Fc receptor of phagocytes |     | ++ | +/− | ++ | + | − | − | − | − |
| Mucosal transport |     | −   | − | − | − | ++ | + | − | − |
| Distribution      |     | Intravascular and extravascular | Intravascular and secretions | Mostly intravascular | Basophils, mast cells in saliva and nasal secretions | Lymphocyte surface |
| Structure         |     | Monomeric | Dimeric | Pentameric | Monomeric | Monomeric |

++, high; +, moderate; +/- minimal; ?, questionable
cellular immune compartment at multiple levels aiming different cells, including dendritic cells, the monocyte/macrophage system, granulocytes, natural killer cells, and various subsets of T cells and B cells [38, 102]. Understanding the mechanisms of interactions between immunoglobulins, immunomodulatory molecules, and cells of the immune system, both innate and adaptive, is the basis for understanding the future therapeutic perspectives of immunoglobulins [38].

Immunoglobulins, upon binding of a specific antigen, stimulate significant direct and indirect “effector functions.” Classically, in bacterial disease, immunoglobulins neutralize toxins, facilitate opsonization, and, with complement, promote bacteriolysis. In viral diseases, immunoglobulins block viral entry into uninfected cells, promote antibody-directed cell-mediated cytotoxicity by natural killer cells, and neutralize virus alone or with the participation with the complement [62]. Furthermore, more recent studies have demonstrated the immunomodulatory functions of antibodies, including the potential for antibody therapy to reduce damage from the host inflammatory response to major infections [24, 25].

Notably, IgG can exert pro- and anti-inflammatory activities depending on its concentration. Low dose of IgG has pro-inflammatory activity and requires complement activation or binding of the Fc fragment from IgG to IgG-specific receptors (FcγR) on innate immune effector cells. This results in receptor clustering, recruitment of secondary effector functions, and subsequent activation of signaling pathways, leading to an increase in intracellular calcium levels and cell activation. By comparison, high concentrations of IgG have anti-inflammatory properties. The mechanisms proposed for this mode of action are modulation of the expression and function of FcγRs, interference with activation of the complement cascade and the cytokine network, neutralization of autoantibodies, and regulation of cell proliferation [38].

Immunoglobulin Preparations

The immunoglobulin preparations used in passive immunization are the standard human serum immunoglobulin, which is available in three forms: immune globulin (IG) for intramuscular use (IMIG), intravenous use (IVIG), and subcutaneous use (SCIG). IMIG is used primarily for the prevention of certain infections, such as hepatitis A, measles, and rubella, and less commonly for the treatment of antibody immunodeficiencies. IVIG is used in the treatment of primary and secondary antibody deficiencies, many immunoregulatory disorders (e.g., immune thrombocytopenic purpura, Kawasaki disease), and neurologic disorders (e.g., Guillain-Barré syndrome, peripheral neuritis). IGSC is used exclusively for the antibody deficiencies.

IVIG preparations comprise the pooled fraction of serum from ~3000 to 60,000 donors, which is generated by a cold ethanol precipitation, providing, thus, a broad spectrum of opsonic and neutralizing IgG antibodies. Opsonic and neutralizing IgG antibody content varies with each product batch, primarily due to differences in the local pathogen ecology of donor exposure. IgG and complement proteins are the principal classes of opsonins contributing to bacterial clearance. In addition to IgG, varying amounts of immunoglobulin isotypes, especially IgA, can be found in the IVIG preparation. Regarding the different human IgG subclasses (IgG1-IgG4), IVIG preparations reflect the hierarchy present in the serum, consisting mainly of IgG1 and IgG2 and containing much smaller amounts of the other IgG subclasses. Only the product Pentaglobin® (Biotest, Germany) is IgM-enriched [93]. The clinical use of IVIG can be distinguished by the infused amount [92]. The principal manufacturing process in all current IgG preparations is cold ethanol fractionation with product-specific additional processes for manufacturing. The commonest processes for virus reduction include solvents/detergent, low pH (pH 4), incubation, nanofiltration, and chromatography [93]. Other major quality control practices in the production process, besides viral reduction, include the depletion of blood coagulation factors and the
removal of IgG aggregates, since these aggregates could result in a cytokine release syndrome owing to the ubiquitous activation of innate immune effector cells via activating FcγRs. IgG aggregations are absent from the majority of IVIG preparation; however, depending on the provider and batch, up to 1–10% of IgG can be found in dimeric form in most IVIG preparations [92].

Immunoglobulins and Clinical Indications

The two major indications for which immunoglobulins are used are IgG replacement therapy and anti-inflammatory therapy in a variety of acute and chronic autoimmune diseases. Apart from immunoglobulin replacement therapy, currently licensed application of immunoglobulin (IVIG) administration includes Guillain-Barré syndrome, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy. Licensed indications, however, only account for approximately 40–50% of the worldwide immunoglobulin sales, as most immunoglobulin administrations are “off-label” [76]. The use of immunoglobulins for infectious disease can involve the passive transfer of antibodies for pre-/postexposure prophylaxis or for treatment. Passive immunization provides temporal immunity to unimmunized individuals either prophylactically or therapeutically. The different forms of passive immunotherapies are shown in Table 17.2 [96].

The technology of ethanol fractionation of plasma resulted in products used for the treatment and prophylaxis of infectious diseases (Table 17.3). Human immune sera have fewer adverse effects, but there are concerns about availability, potency, and consistency.

Table 17.4 summarizes the adverse reactions of immunoglobulin used in the prevention and treatment of infectious diseases.

Immunoglobulins to Prevent Infections in Immunodeficiencies

Administration of immunoglobulins is indicated for the majority of patients with primary immune deficiencies and for patients with combined immune deficiencies and for those with secondary immune deficiency with significant antibody deficiency. The benefits of replacement immunoglobulin therapy for the prevention of infections in patients with antibody deficiencies are well established and pertain to the reduction of the incidence and the severity of infections and prevention long-term deterioration in organ function [12, 13].

Primary immune deficiencies (PIDD) are one of the US Food and Drug Administration (FDA)-approved indications for immunoglobulin therapy. Over 80% of all PIDD involve antibody-mediated immunity; however, each individual disorder has a different immunopathogenesis in terms of the number of B cells in the blood and B-cell function. Moreover, any persisting endogenous antibody production varies both between specific conditions and within individual disorders [10, 35, 97]. Table 17.5 describes the PIDD for which immunoglobulin replacement is or may be efficacious. The recommendations for immunoglobulin replacement treatment in primary and secondary immune deficiencies are shown in Table 17.6 [32, 84, 97]. The main indications are primary antibody deficiencies including agammaglobulinemia (autosomal recessive or X-linked) and common variable immunodeficiency disorders. Rarely, other
| Infection | Prophylaxis | Treatment | Recommendations | Immunoglobulin preparations used |
|-----------|-------------|-----------|-----------------|----------------------------------|
| Respiratory infections (streptococcal, *Streptococcus pneumonia, Neisseria meningitidis, Haemophilus influenzae*) | Proven | Proven | For prophylaxis and treatment: recommended for immunodeficient patients | IVIG or IMIG |
| Diphtheria | Probable benefit | Proven | For prophylaxis: not recommended | Diphtheria antitoxin of equine origin |
| Pertussis | Unproven | Unproven | For prophylaxis and treatment: not recommended | No agent is available for passive immunity, high titer human IVIG was used |
| Tetanus | Proven | Proven | | Hyperimmune human tetanus immunoglobulin (TIG), human IVIG can be used when TIG is not available, equine tetanus antitoxin is available for veterinary use |
| Clostridium botulinum | Proven | Proven | | Botulinum antitoxins (heptavalent) |
| Newborn botulism | Unproven | Proven | | Human botulinum intravenous immunoglobulin (BIG) |
| Clostridium difficile | Unproven | Possible benefit | | IVIG, monoclonal antibodies for prevention of recurrence of diarrhea under development |
| Staphylococcal infections | | | | |
| Toxic shock syndrome | Unproven | Probable benefit | For prophylaxis: not recommended for toxic shock syndrome | IVIG |
| Antibiotic resistance | Unproven | Possible benefit | For treatment: not recommended in cases of antibiotic resistance | IVIG |
| Staphylococcus epidermidis in newborns | Unproven | Possible benefit | | IVIG |
| Toxic shock | Unproven | Probable benefit | For prophylaxis: not recommended | IVIG |
| Newborn sepsis | Possible benefit | Probable benefit | For prophylaxis: not recommended | IVIG |
| Shock, intensive care, and trauma | Unproven | Possible benefit | For treatment: not recommended | IVIG |
### Pseudomonas infections

| Condition       | Status   | Benefit      | Prophylaxis and Treatment               | Immunoglobulin |
|-----------------|----------|--------------|----------------------------------------|----------------|
| Cystic fibrosis | Unproven | No benefit   | For prophylaxis and treatment: not recommended | IVIG           |
| Burns           | Unproven | No benefit   | For prophylaxis and treatment: not recommended | IVIG or IMIG   |

### Viral diseases

| Condition       | Status   | Benefit      | Prophylaxis and Treatment               | Immunoglobulin |
|-----------------|----------|--------------|----------------------------------------|----------------|
| Hepatitis A     | Proven   | No benefit   | IMIG                                   |                |
| Hepatitis B     | Proven   | No benefit   | Hepatitis B immune globulin (HBIG) for subcutaneous or intramuscular use |                |
| Hepatitis C     | Unproven | No benefit   | For prophylaxis: not recommended        |                |
| HIV infection   | Unproven | Unproven     | For prophylaxis and treatment: not recommended | Monoclonal antibodies under development |
| RSV infection   | Proven   | Unproven     | For treatment: not recommended          | Palivizumab    |

### Herpesvirus infections

| Condition       | Status   | Benefit      | Prophylaxis and Treatment               | Immunoglobulin |
|-----------------|----------|--------------|----------------------------------------|----------------|
| CMV             | Proven   | Possible benefit | CMV immune globulin                      |                |
| EBV             | Unproven | Unproven     | For prophylaxis and treatment: not recommended | Rituximab      |
| HSV             | Unproven | Unproven     | For prophylaxis and treatment: not recommended | IVIG not recommended for the prevention or treatment of HSV |
| VZV             | Proven   | Unproven     | For treatment: not recommended          | Varicella-zoster immune globulin (VZIG) or IVIG |
| Parvovirus      | Possible benefit | Proven | For treatment: not recommended          | IVIG           |

### Enterovirus infections

| Condition       | Status   | Benefit      | Prophylaxis and Treatment               | Immunoglobulin |
|-----------------|----------|--------------|----------------------------------------|----------------|
| In newborns     | Unproven | Possible benefit | IVIG or IMIG                           |                |
| Encephalomyelitis | Possible benefit | Probable benefit | For treatment: not recommended         | IVIG           |
| Poliovirus      | Proven   | Unproven     | For prophylaxis and treatment: not recommended | IMIG           |
| Ebola           | Unproven | Unproven     | Hyperimmune serum, monoclonal antibodies under development |                |
| Rabies          | Proven   | No benefit   | Rabies immune globulin, monoclonal antibodies under development |                |
| Measles         | Proven   | No benefit   | IGIM or IVIG                            |                |
| Rubella         | Unproven | No benefit   | For prophylaxis: not recommended        | IGIM           |

(continued)
| Infection               | Prophylaxis | Treatment | Recommendations                  | Immunoglobulin preparations used                                                                 |
|-------------------------|-------------|-----------|-----------------------------------|---------------------------------------------------------------------------------------------------|
| Mumps                   | Unproven    | No benefit| For prophylaxis: not recommended  | Mumps immune globulin was ineffective, the product no longer manufactured                          |
| Tick-borne encephalitis | Possible    | No benefit|                                   | Hyperimmune human globulin                                                                        |
| Vaccinia                | Proven      | Proven    |                                   | Vaccinia immune globulin                                                                          |
| Variola (smallpox)      | Proven      | Unproven  |                                   | Vaccinia immune globulin                                                                          |

Modified from: Stiehm and Keller [120]

CMV cytomegalovirus, EBV Epstein-Barr virus, HIV human immunodeficiency virus, HSV herpes simplex virus, RSV respiratory syncytial virus, VZV varicella-zoster virus, IVIG standard human immune globulin intravenous, IMIG immune globulin intramuscular
antibody deficiencies, such as IgG subclass deficiency, may be managed by immunoglobulin replacement. In these immunodeficiencies, a trial of 12 months may be indicated if there is a substantial infection burden. On the contrary, for selective IgA deficiency, immunoglobulin replacement is not required or recommended, as anaphylactic reactions may occur during IVIG infusions. Combined immunodeficiencies with antibody deficiency also benefit from immunoglobulin therapy until the defects in cell-mediated immunity are corrected by hematopoietic stem cell transplantation. However, B-cell function is not restored universally after transplantation, and immunoglobulin therapy may be continued [86]. It is important that each patient receives a thorough evaluation before starting immunoglobulin therapy especially those with partial antibody defects.

The American Academy of Allergy, Asthma, and Immunology, based on a 2006 review of evidence, recommends for PIDD the dose of 400–600 mg/kg of IVIG every 4 weeks, titrating the dose and interval between infusions to achieve a trough IgG level at least greater than 500 mg/dl in agammaglobulinemic patients [84]. However, recent evidence suggests that the goal of IgG replacement therapy should be to reduce or prevent serious or recurrent infections instead of aiming to achieve a specific IgG level. The clinicians should identify for each patient with PIDD an individual “biological” IgG level with which the patient achieves the best clinical outcome instead of trying to reach a specific IgG level [16, 17].

The two modes of IgG replacement (IVIG and SCIG) have significant pharmacokinetic differences, which are important to know when choosing the mode of IgG delivery or switching from IVIG to SCIG. SCIG causes sustained release of IgG and thus attains higher IgG trough levels; this mode of delivery may benefit the 10–15% of patients who show increased risk of infection during the 3rd and 4th weeks after receiving IVIG or who experience extreme lethargy during the same period. IVIG achieves higher peak levels (160% higher than that obtained by SC infusion), and this mode of delivery is usually initially preferred for patients with PIDD who are very symptomatic (present with pneumonia or other serious infectious such as sepsis) and who present with pneumonia or for those with other medical problems such as sepsis [16].

IVIG has also been used in a number of diseases that cause secondary humoral immunodeficiency. While for the majority of secondary immunodeficiencies, the use of IVIG was supported only by anecdotal reports, and B-cell chronic lymphocytic leukemia (CLL) and pediatric HIV infection are FDA-approved indications. For both, CLL and HIV, infections are the most common complications. IVIG has been shown to be a useful prophylactic therapy against infections in such patients [29, 53, 54, 72, 95, 110].

| Table 17.4 Adverse effects due to immunoglobulin therapy |
|---------------------------------|
| Adverse reaction | Frequency | Severity |
| Infusion site pain, swelling, erythema | Up to 75% in SCIG | Usually mild |
| Anxiety | 20–40% | |
| Malaise, fatigue | | |
| Myalgia, arthralgia, back pain | | |
| Fever, chills, flushing | | |
| Tachycardia | | |
| Hypo-/hypertension | | |
| Headache | | |
| Aseptic meningitis | <5% | Moderate |
| Hyponatremia | | Moderate |
| Neutropenia | | Mild/ transient |
| Hemolytic anemia | | Moderate to severe |
| Interference with vaccine effectiveness and/or immunodiagnosis | | N/A |
| Eczema | | |
| Renal impairment | | |
| Anaphylactoid reaction | <0.1% | |
| Severe thrombosis | | |
| Blood-borne infectious diseases | | |

Modified from: Peter and Chapel [86]

SCIG subcutaneous immunoglobulin, N/A not applicable
*Frequencies are for patients using long-term therapy
| Primary Immunodeficiency | Immunologic Findings | Immunoglobulin Replacement | Immunoglobulin Cessation |
|--------------------------|----------------------|----------------------------|-------------------------|
| **Antibody Deficiency**  |                      |                            |                         |
| X-linked or autosomal agammaglobulinemia | <1% normal B cells, agammaglobulinemia, poor specific antibodies | Absolute indication, start immediately | Lifelong replacement |
| Common variable immunodeficiency disorders (CVID) | Hypogammaglobulinemia, poor specific antibodies, variable T-cell abnormalities | Absolute indication, start immediately | Lifelong replacement |
| IgG subclass deficiency with IgA deficiency | IgG subclass deficiency (usually IgG2), absent IgA, poor specific antibodies | Replacement only in symptomatic patients (clinically significant infections) | Reassessment for efficacy after 12-month treatment trial |
| Selective IgG subclass deficiency | Single IgG subclass deficiency, normal total IgG, poor specific antibodies | Replacement may not be necessary |                         |
| Specific antibody deficiency with recurrent infections | Normal IgG, IgA, IgM, abnormal IgG antibody responses to protein and/or unconjugated polysaccharide vaccines | Consider replacement if patient has vaccine unresponsiveness and clinically significant infections | Reassessment for efficacy after 12-month treatment trial, watch for development of more severe antibody failure |
| Transient hypogammaglobulinemia of infancy | Low serum IgG and IgA, poor specific antibodies | Preferable to use prophylactic antibiotics as deficiency is transient, some are given replacement for a period | Replacement stopped after some months to ascertain recovery |
| **Combined Immunodeficiencies** |                      |                            |                         |
| Severe combined immunodeficiencies (SCIDs) | Absent or severely reduced lymphocytes and no antibody production | Replacement is required prior to HSCT | If B-cell reconstitution fails, replacement may still be required after HSCT |
| NEMO deficiency | Reduced IgG; IgA or IgM may be increased; B cells present | Replacement is required | Cessation inappropriate except after successful HSCT |
| X-linked lymphoproliferative syndromes | May have reduced B cells and low IgG and IgA levels post EBV infection | Consider replacement | Cessation inappropriate unless HSCT is successful |
| Hyper-IgE syndromes | IgE elevated, sometimes reduced class switching and low levels of IgA and IgG subclasses with poor antibody responses | Replacement in selected patients | Cessation inappropriate if antibody failure confirmed |
| Wiskott-Aldrich syndrome | Decreased lymphocytes, variable defects in T-, B-, and NK-cell function, variable IgM, normal or elevated IgA, elevated IgG and IgE, often abnormal IgG antibody response to unconjugated polysaccharide vaccines | Consider replacement | Cessation inappropriate if antibody failure confirmed until successful HSCT |

(continued)
Administration of IVIG in CLL patients with hypogammaglobulinemia has been shown to decrease the rate of bacterial infections; however, decision analysis modeling showed that this decrease might not improve the length or quality of treated patients’ lives, and, furthermore, it is extraordinarily expensive [110]. The prophylactic administration of IVIG in CLL patients has not been studied extensively, and, thus, there are no guidelines to define the patient population that would benefit from this treatment; also the optimal dosing and timing of IVIG administration remained to be defined. Some experts support the use of IVIG in selected cases, depending on the history of the patient and especially in patients that IVIG has been shown to work in the past.

IVIG therapy together with antiviral therapy was beneficial in infants and children with AIDS and hypogammaglobulinemia or two or more bacterial infections in the previous year. Other indications for IVIG therapy in HIV-infected patients include those with severe parvovirus B19 or measles infection [72, 95, 119]. However, it is important to note that these studies occurred before the era of highly active antiretroviral treatment for HIV [84].

Transplantation

IVIG has been utilized in allogeneic bone marrow transplantation (BMT) in an attempt to decrease the incidence of cytomegalovirus (CMV) infection, infections due to other pathogens, and graft-versus-host disease (GVHD). Immunoglobulin use in the setting of BMT is FDA approved. The rationale for using IVIG in transplantation is that the administration of passive antibodies may prevent infections in these immunocompromised patients and especially infections caused by CMV [84]. Several randomized controlled trials provided the basis to recommend IVIG after allogeneic BMT [19, 31, 46, 87, 98, 116, 117]. Meta-analysis of these trials found significant reduction of fatal CMV infections, CMV pneumonia, non-CMV interstitial pneumonia, and transplant-related mortality.

| Table 17.5 | (continued) |
|------------|-------------|
| Primary immunodeficiency | Immunologic findings | Immunoglobulin replacement | Immunoglobulin cessation |
| Ataxia-telangiectasia | Partial antibody deficiency in some cases | Replacement in selected patients | Cessation inappropriate if antibody failure confirmed |
| Hyper-IgM syndromes | Normal or elevated IgM, low or absent IgG, IgA and IgE, poor specific antibodies, variable T-cell abnormalities | Start replacement at the time of diagnosis until successful HSCT | Cessation inappropriate |

Modified from Peter and Chapel, Immunotherapy 2014; 6: 853–869, Albin and Cunningham-Rundles, Immunotherapy 2014; 6: 1113–1126

EBV Epstein-Barr virus, HSCT human stem cell transplantation, NEMO NF-κB essential modulator

| Table 17.6 | Recommendations for the use of immunoglobulins in immune deficiencies |
|-------------|---------------------------|
| Benefit     | Disease                    |
| Definitely beneficial | Primary immune defects with absent B cells |
|             | Primary immune defects with hypogammaglobulinemia and impaired specific antibody production |
| Probably beneficial | Chronic lymphocytic leukemia with reduced IgG and history of infections |
|             | Prevention of bacterial infections in HIV-infected children |
|             | Primary immune defects with normo-gammaglobulinemia and impaired specific antibody production |
| Unlikely to be beneficial | Isolated IgA deficiency |
|             | Isolated IgG4 deficiency |

The recommendations for immunoglobulin indications according to the Primary Immunodeficiencies Committee of the American Academy of Allergy, Asthma, and Immunology; 2006
among patients receiving prophylactic IVIG [11]. While an improvement in survival was reported in some studies [46, 49, 118], a more recent meta-analysis showed that IVIG or hyperimmune CMV-IVIG had no effect on the reduction of all-cause mortality [90]. Collectively, the data regarding the benefit of prophylactic administration of IVIG after BMT remain controversial and contradictory. In addition, until currently, there is no consensus on the type, schedule, dose, and patients benefiting from IVIG. Subsequent studies suggested that double prophylaxis consisting of high-dose IVIG and ganciclovir was more successful than either treatment alone in reversing CMV pneumonia in patients after BMT [39, 69]. The American Society for Blood and Marrow Transplantation does not recommend the routine use of IVIG to hematopoietic cell transplant recipients for prophylaxis for CMV disease or for bacterial infections within the first 100 days after transplantation. For patients with severe hypogammaglobulinemia (IgG <400 mg/dl), IVIG prophylaxis of bacterial infections may be considered. IVIG dose and frequency for these patients should be individualized to maintain trough serum IgG concentrations >400 mg/dl [103]. Routine use of IVIG appears to offer little benefit to patients with malignancies undergoing HLA-identical sibling BMT [84]. Given that the landscape of patients receiving BMT is evolving, it is likely that the available data are outdated, and more updated randomized trials are warranted to inform clinical practice.

GVHD and infection are major complications of allogeneic BMT. In vitro and in vivo experimental models showed that the prevention of acute GVHD by IVIG is mediated by the induction of apoptosis of activated alloreactive CD4+ expressing CD134+ donor T cells and reducing the amount of IFN-γ produced by donor T cells [22]. IVIG was shown to decrease the severity of acute GVHD in recipients of allogeneic BMT [98, 116, 117]. On the contrary, administration of IVIG prophylaxis has no effect on the incidence or mortality of chronic GVHD on BMT [99]. While there is no consensus on the optimal dose of IVIG, it appears that the incidence of acute GVHD is less in patients receiving higher doses of IVIG. The benefits of IVIG appear to correlate with IgG trough levels where acute GVHD was less frequent among patients achieving maximum serum IgG levels ≥3000 mg/dl after the administration of IVIG. Trough serum IgG levels >1200 mg/dl were associated with less severe acute GVHD [1, 33, 40].

Over the last decade, IVIG usage in solid organ transplantation has increased significantly. There are encouraging data on the role of IVIG for the treatment of antibody-mediated rejection, desensitization to HLA and/or ABO antigens, as well as prevention and treatment of infectious complications for patients undergoing solid organ transplantation [74, 94]. There is also some evidence that IVIG may be useful for the treatment of autoimmunity cytopenias after solid organ transplantation [91]. Dosing of IVIG is empiric although higher than those for replacement therapy. Especially for the treatment of antibody-mediated rejection, the dose is 1–2 gm/kg [23, 38, 58, 60, 61, 76]. The use of higher doses of IVIG is related to higher rates of adverse events. These include aseptic meningitis thrombotic events and bronchospasm [59].

### Immunoglobulin Therapy for Sepsis and Septic Shock

Sepsis is the systemic inflammatory response of the host to an infectious insult. Severe sepsis is characterized by acute organ dysfunction, while septic shock is characterized by hypotension, which is refractory to fluid replacement, or by hyperlactatemia [9]. Severe sepsis and septic shock represent one of the oldest and most pressing problems in medicine. Care of patients with sepsis has improved over the last decades; however, the incidence of sepsis is increasing along with morbidity and mortality rates especially in critically ill adults. Worldwide, the annual incidence of severe sepsis lies between 100 and 300 cases per 100,000 population, and mortality for severe sepsis and septic shock reaches 30% and 50%, respectively [8, 56, 73, 109]. While our understanding of the underlying biologic features of sepsis has made significant
progress, the clinical assessment of several new strategies for implementation for sepsis treatment has led to disappointing results [3, 7, 15, 18, 108]. There have been more than 100 randomized clinical trials of strategies to modify the systemic inflammatory response during sepsis; however, no strategy showed to improve dramatically the survival of patients with sepsis [71].

The development of highly purified human plasma-derived polyclonal IVIGs presented a very compelling therapy for severe infections including sepsis and septic shock. IVIGs have broad and potent activity against microorganisms, their extracellular products, and potent immunomodulatory effects [78]. IVIG preparations, in particular IgM-enriched preparations, contain antibodies against lipopolysaccharides of *Escherichia coli*, *Pseudomonas aeruginosa*, and *Klebsiella* spp. [104]. The effects of IVIGs on the sepsis-induced host response seem to be pleotropic, not yet completely clarified, and are likely to be secondary to both suppression of synthesis and direct scavenging of upstream and downstream mediators of the host response and complex immunomodulatory effects [93].

The cellular effects of immunoglobulins are mediated through the IgG constant fragment (Fc). Immunoglobulin acts as an adaptor between the innate and adaptive immune system by interacting with Fc, which mediate both pro- and anti-inflammatory signals. IVIGs have direct antibacterial effects through pathogen recognition and increased clearance. IVIGs also have anti-inflammatory properties mediated by the scavenging of bacterial toxins and pro-inflammatory cytokines, by immune cell depletion, by the blockade of activating receptors, and by modulating FcγR expression, dendritic cell activity, and T-cell expansion [77, 92, 93].

The challenging pathobiology of sepsis is associated with acquired hypogammaglobulinemia, which seems to prevent optimal pathogen clearance and pathogen toxin scavenging [100, 107, 113]. Furthermore, sepsis, by causing endothelial dysfunction and capillary leak together with the iatrogenic fluid resuscitation-related increase in extravascular volume, eventually causes an alteration in the distribution of immunoglobulins [93]. Consequently, it is logical to predict that the administration of IVIG during sepsis would be of benefit.

In the clinical setting, the role of IVIG as an adjunctive treatment in sepsis has been controversial for years. A number of randomized placebo-controlled clinical trials in adult critical care patients evaluating standard polyclonal IVIG- or IgM-enriched polyclonal adjunctive therapy in severe sepsis as well as the meta-analyses of these trials have been published [5, 65, 67, 75, 88, 105]. Positive findings of controlled trials and anecdotal reports have been criticized for methodological weakness including the small number of the patients and adequacy of blinding. The more recent studies, which were more meticulously designed, have shown much less effect of IVIG than older, smaller, and less well-designed studies [50]. Of note, the studies that used albumin as control showed less benefit of IVIG than those that did not [41]. The Score-Based Immunoglobulin G Treatment in Sepsis (SBITS) study, one carefully designed, large study representing almost half of all the adults studied to date, showed no reduction in mortality by IVIG in patients with score-defined sepsis and sepsis-induced multi-organ failure [113].

The first clinical trial, which evaluated the effect of IgMA-enriched immunoglobulin preparation (7.8 g IgM, 7.8 g IgA, and 49.4 g IgG), which have shown to contain superior antibody content against bacterial lipopolysaccharides, in an appreciable number of neutropenic patients with hematologic malignancies and sepsis or septic shock, showed that immunoglobulins had no beneficial effects [51]. However, as the editor comments, the study, with a high evidence level, demonstrates that neutropenic patients with malignancies and low-grade sepsis with no or only one organ failure will not benefit from adjunctive IVIG treatment [111].

The prophylaxis and treatment of neonatal sepsis has been a major global priority, and large international trials have been carried out testing IVIG ([57, 79–83]; Group et al. 2011). Mortality during hospital stay in infants with clinically suspected infection at trial entry was not significantly different after IVIG treatment [81]. The
results of the International Neonatal Immunotherapy Study (INIS) and recent meta-analyses showed that IVIG did not reduce mortality during hospital stay or major disability at 2 years of age in infants with sepsis [48, 83]. Based on the results of the INIS trial (3493 subjects), routine administration of IVIG to prevent mortality in infants with sepsis is not currently recommended [48].

When considering the administration of IVIG during sepsis, important aspects that should be taken into account are the dose, the type, the timing, and pharmacokinetics of IVIG [6, 50]. While dose-ranging studies have not been completed, studies that used high (>1 g/kg body weight) doses of IVIG demonstrated better effects. This seems plausible given the clinical observations in other inflammatory conditions, such as Kawasaki disease, where greater effect was noted with higher doses [52]. The type of IVIG may have an important effect, possibly in favor of a greater pooled effect of IgMA-enriched compared with standard preparations of IVIG. IgMA-enriched preparations are associated with greater complement inactivation and improvement in microvascular perfusion in experimental models [112]. However, collectively, the results from animal models and in vitro experiments show contradictory results and do not allow for a definite conclusion regarding the superiority of one specific immunoglobulin preparation in patients with sepsis. In an efficacy study, administration of polyclonal IgG versus IgMA in selected patients at high risk for sepsis was associated with a comparable improvement in disease severity [89].

Regarding the timing of IVIG administration during sepsis, there is probably a “window of opportunity” in the first days that follow clinical presentation of sepsis [14]. If this window is missed, probabilities of success could be greatly diminished [6]. Pharmacokinetic studies of IVIG in sepsis have not been performed yet. Data for dosage selection in current practice are primarily derived from studies in volunteers and in patients with primary immune deficiencies and other indications for immunomodulation. Existing pharmacokinetic studies also do not address immunoglobulin clearance or area under the curve parameters and target serum immunoglobulin concentrations [64]. In addition, it is still unknown whether the main goal of IVIG in sepsis is to refill low levels of endogenous immunoglobulins or alternatively whether IVIG could exert a beneficial effect regardless of these levels [6].

Most studies evaluating the use of IVIG for sepsis are small; some have methodological flaws and high-quality, large studies showed no effect [48, 113]. Given immunoglobulin high-cost, limited supply and the lack of strong evidence to support their beneficial effect, widely used guidelines either neglect or grade as a weak recommendation the use of polyclonal IVIG in sepsis [36]. While clinical judgment may guide immunoglobulin use in individual cases, particularly those due to Gram-negative etiologies or streptococcal toxic shock syndrome, these practices are based largely on theoretical rationale, anecdotal, and retrospective clinical observations [50, 66, 106].

The effect of monoclonal antibodies against tumor necrosis factor (TNF)-α has been evaluated in a series of trials on different anti-TNF-α-directed therapies [4, 30, 37, 42]. The long-anticipated sepsis trial (MONARCS [Monoclonal Anti-TNF, A Randomized Controlled Sepsis trial]) reported that afelimomab, which is made up of the Fab component of a monoclonal antibody against TNF-α, in patients with severe sepsis and elevated IL-6 levels decreased mortality and had a safety profile similar to placebo [85]. However, combining the results of these studies, a small improvement in mortality can be detected [34, 47]. As sepsis is increasingly being considered as an exaggerated, poorly regulated innate immune response to microbial products, by the time of diagnosis, an entire network of cytokines has already been activated. In this regard, the results of the previous studies would have been anticipated, as it seems unlikely that therapy aimed at only one cytokine would by itself have the highly significantly impact on sepsis mortality [34].
Future Directions

Immunoglobulins have been used widely in medicine for a variety of diseases including infectious diseases. While the two major indications for immunoglobulin use are as replacement and anti-inflammatory therapy in a variety of acute and chronic autoimmune diseases, their use in the prevention and treatment of infectious diseases is emerging as an attractive option especially in the era of multi-antibiotic resistance. Many aspects of immunoglobulin therapy remain controversial and contradictory. Consequently, immunoglobulin use is sometimes determined by clinical judgment or expert opinion, which is based largely on theoretical rationale, anecdotal, and retrospective clinical observations. Gaps of knowledge that need to be addressed are certain categories of patient populations that would benefit from immunoglobulin treatment or prophylaxis, the optimal immunoglobulin dosing, and duration, as well as timing of administration.

Monoclonal antibody technology has opened a new era in antibody therapy. On many occasions, human monoclonal antibodies have better therapeutic properties than immunoglobulins including low toxicity, longer protective immunity, higher than natural protection, and high specificity. Several antibodies for the treatment of bacterial and viral infections have been developed [101]. However, some challenges need to be overcome before they become preferred agents for the treatment and prophylaxis against infectious diseases.

Biofilms are now acknowledged to contribute to a plethora of chronic and recurrent infections. While treatment or eradication of biofilm-related infections is still challenging, there are sufficient in vitro and preclinical data to support the use of antibodies directed against extracellular DNA-binding proteins entrapped into the extracellular biofilm polymeric substrate [20, 44]. While still an area of ongoing preclinical and clinical research, this use of antibodies constitutes a novel therapeutic approach for treatment of biofilm-related infections.

References

1. Abdel-Mageed A, Graham-Pole J, Del Rosario ML, Longmate J, Ochoa S, Amylon M, et al. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants. Bone Marrow Transplant. 1999;23(9):929–32. https://doi.org/10.1038/sj.bmt.1701742.
2. Abolhassani H, Asgardooni MH, Rezaei N, Hammarsstrom L, Aghamohammadi A. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient? Expert Rev Clin Immunol. 2015;11(11):1229–43. https://doi.org/10.1586/1744666X.2015.1079485.
3. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290(2):238–47. https://doi.org/10.1001/jama.290.2.238.
4. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995;273(12):934–41.
5. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev. 2002;1:CD001090. https://doi.org/10.1002/14651858.CD001090.
6. Almansa R, Tamayo E, Andaluz-Ojeda D, Nogales L, Blanco J, Eiros JM, et al. The original sins of clinical trials with intravenous immunoglobulins in sepsis. Crit Care. 2015;19:90. https://doi.org/10.1186/s13054-015-0793-0.
7. Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, et al. E5 murine monoclonal antienodotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA. 2000;283(13):1723–30.
8. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Cercillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–10.
9. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840–51. https://doi.org/10.1056/NEJMra1208623.
10. Ballou M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, et al. Immunodeficiencies. Clin Exp Immunol. 2009;158(Suppl 1):14–22. https://doi.org/10.1111/j.1600-0625.2009.00423.x.
11. Bass EB, Powe NR, Goodman SN, Graziano SL, Griffiths RI, Kickler TS, et al. Efficacy of immune globulin in preventing complications of bone mar-
row transplantation: a meta-analysis. Bone Marrow Transplant. 1993;12(3):273–82.
12. Berger M. Goals of therapy in antibody deficiency syndromes. J Allergy Clin Immunol. 1999;104(5):911–3.
13. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin N Am. 2008;28(2):413–37. https://doi.org/10.1016/j.iac.2008.01.008.
14. Berlot G, Vassallo MC, Busetto N, Bianchi M, Zornada F, Rossato I, et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care. 2012;27(2):167–71. https://doi.org/10.1016/j.jcrc.2011.05.012.
15. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997;336(13):912–8. https://doi.org/10.1056/NEJM199709043361301.
16. Bonagura VR. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. J Clin Immunol. 2013;33(Suppl 2):S90–4. https://doi.org/10.1007/s10875-012-9838-1.
17. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immune deficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122(1):210–2. https://doi.org/10.1016/j.jaci.2008.04.044.
18. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317(11):653–8. https://doi.org/10.1056/NEJM198709103171101.
19. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314(16):1006–10. https://doi.org/10.1056/NEJM198604173141602.
20. Brockson ME, Novotny LA, Mokrzan EM, Malhotra S, Jurcisek JA, Akbar R, et al. Evaluation of the kinetics and mechanism of action of anti-integration host factor-mediated disruption of bacterial biofilms. Mol Microbiol. 2014;93(6):1246–58. https://doi.org/10.1111/mmi.12755.
21. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722–8.
22. Caccavelli L, Field AC, Betin V, Dreillard L, Belair MF, Bloch MF, et al. Normal IgG protects against acute graft-versus-host disease by targeting CD4(+)/CD134(+) donor alloreactive T cells. Eur J Immunol. 2001;31(9):2781–90. https://doi.org/10.1002/1521-4141(200109)31:9<2781.AID-IMMU2781>3.0.CO;2-Z.
23. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994;38(8):1695–702.
24. Casadevall A, Scharff MD. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol. 2006;91:1–44. https://doi.org/10.1016/S0065-2776(06)91001-3.
25. Casadevall A, Pirofski LA. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 2003;24(9):474–8.
26. Casadevall A, Pirofski LA. A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Ann Intern Med. 2003;138(6):502–5.
27. Cunningham-Rundles C. Key aspects for successful immunoglobulin therapy of primary immunodeficiencies. Clin Exp Immunol.
17 Role of Immunoglobulin Therapy to Prevent and Treat Infections

355

2011;164(Suppl 2):16–9. https://doi.org/10.1111/j.1365-2249.2011.04390.x.

36. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228. https://doi.org/10.1007/s00134-012-2769-9.

37. Dhainaut JF, Vincent JL, Richard C, Lejeune P, Martin C, Fierebo L, et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med. 1995;23(9):1461–9.

38. Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, et al. Intravenous immunoglobulins – understanding properties and mechanisms. Clin Exp Immunol. 2009;158(Suppl 1):2–13. https://doi.org/10.1111/j.1365-2249.2009.04022.x.

39. Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109(10):777–82.

40. Feinstein LC, Sieidel K, Jocum J, Bowden RA, Anasetti C, Deeg HJ, et al. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant. 1999;5(6):369–78.

41. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247–56. https://doi.org/10.1056/NEJMoa040232.

42. Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med. 1993;21(3):318–27.

43. Flexner S. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med. 1913;17(5):553–76.

44. Goodman SD, Oberfell KP, Jurcisek JA, Novotny LA, Downey JS, Ayala EA, et al. Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins. Mucosal Immunol. 2011;4(6):625–37. https://doi.org/10.1038/mi.2011.27.

45. Graham BS, Ambrosino DM. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS. 2015;10(3):129–34. https://doi.org/10.1097/COH.0000000000000154.

46. Graham-Pole J, Camitta B, Casper J, Elfenbein G, Gross S, Herzig R, et al. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study. Bone Marrow Transplant. 1988;3(6):559–66.

47. Grass G, Neugebauer EA. Afelimomab—another therapeutic option in sepsis therapy? Crit Care Med. 2004;32(11):2343–4.

48. Group IC, Brocklehurst P, Farrell B, King A, Juszczak E, Darlow B, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med. 2011;365(13):1201–11. https://doi.org/10.1056/NEJMoa1100441.

49. Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant. 1994;13(5):499–510.

50. Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles C. Clinical applications of intravenous immunoglobulins (IVIg) – beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009;158(Suppl 1):23–33. https://doi.org/10.1111/j.1365-2249.2009.04024.x.

51. Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, et al. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med. 2006;34(5):1319–25. https://doi.org/10.1097/01.CCM.0000215452.84291.C6.

52. Imbach P, Barandun S, d’Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1(8232):1228–31.

53. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991;325(2):73–80. https://doi.org/10.1056/NEJM199101113250201.

54. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319(14):902–7. https://doi.org/10.1056/NEJM198810063191403.

55. Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol. 2015;67(2 Pt A):171–82. https://doi.org/10.1016/j.molimm.2015.03.255.

56. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304(16):1787–94. https://doi.org/10.1001/jama.2010.1553.
70. Llewelyn MB, Hawkins RE, Russell SJ. Discovery of antibodies. BMJ. 1992;305(6864):1269–72.

71. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20(4):195–203. https://doi.org/10.1016/j.molmed.2014.01.007.

72. Mofenson LM, Moye J Jr, Kotelitz J, Bethel J, Hirschhorn R, Nugent R. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Pediatr Infect Dis J. 1994;13(6):477–84.

73. Moss M. Epidemiology of sepsis: race, sex, and chronic alcohol abuse. Clin Infect Dis. 2005;41(Suppl 7):S490–7. https://doi.org/10.1086/432003.

74. Nahirniak S, Hume HA. Guidelines for the use of immunoglobulin therapy for primary immune deficiency and solid organ transplantation. Transfus Med Rev. 2010;24(Suppl 1):S1–6. https://doi.org/10.1016/j.tmrv.2009.09.009.

75. Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care. 2005;20(3):239–49. https://doi.org/10.1016/j.jcrc.2005.03.003.

76. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008a;26:513–33. https://doi.org/10.1146/annurev.immunol.26.021607.090232.

77. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008a;26:513–33. https://doi.org/10.1100/nri2206.

78. Norbury-Teglund A, Haque KN, Hammarstrom L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med. 2006;260(6):509–16. https://doi.org/10.1111/j.1365-2796.2006.01726.x.

79. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev. 2004a;1:CD000361. https://doi.org/10.1002/14651858.CD000361.pub2.

80. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev. 2004b;1:CD001239. https://doi.org/10.1002/14651858.CD001239.pub2.

81. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2013a;7:CD000361. https://doi.org/10.1002/14651858.CD000361.pub3.

82. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev. 2013b;7:CD001239. https://doi.org/10.1002/14651858.CD001239.pub4.

83. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates.
94. Shehata N, Palda VA, Meyer RM, Blydt-Hansen U, Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev. 2010;24(Suppl 1):S25–53. https://doi.org/10.1016/j.tmrv.2009.09.010.

95. Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med. 1994;331(18):1181–7. https://doi.org/10.1056/NEJM19941103311802.

96. Stiehm ER, Ashida E, Kim KS, Winston DJ, Haas A, Gale RP. Intravenous immunoglobulins as therapeutic agents. Ann Intern Med. 1987;107(3):367–82.

97. Stiehm ER, Orange JS, Ballow M, Lehman H. Therapeutic use of immunoglobulins. Adv Pediatr Infect Dis. 2010;57(1):185–218. https://doi.org/10.1016/j.yapd.2010.08.005.

98. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323(11):705–12. https://doi.org/10.1056/NEJM199009133231103.

99. Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant. 1996;2(1):44–53.

100. Taccone FS, Stordeur P, De Backer D, Creteur J, Vincent JL. Gamma-globulin levels in patients with community-acquired septic shock. Shock. 2009;32(4):379–85. https://doi.org/10.1097/SHK.0b013e3181a2c0b2.

101. Ter Meulen J. Monoclonal antibodies in infectious diseases: clinical pipeline in 2011. Infect Dis Clin N Am. 2011;25(4):789–802. https://doi.org/10.1016/j.idc.2011.07.006.

102. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 2008;29(12):608–15. https://doi.org/10.1016/j.it.2008.08.004.

103. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238. https://doi.org/10.1016/j.bbmt.2009.06.019.

104. Trautmann M, Held TK, Susa M, Karajan MA, Wulf H, Barzilai A, et al. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clin Exp Immunol. 1998;111(1):81–90.

105. Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tim Mouth AA, Cameron DW, et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med. 2007;146(3):193–203.
106. Valiquette L, Low DE, Chow R, McGeer AJ. A survey of physician’s attitudes regarding management of severe group a streptococcal infections. Scand J Infect Dis. 2006;38(11–12):977–82. https://doi.org/10.1080/00365540600786499.

107. Venet F, Gebeile R, Bancel J, Guignant C, Poitevin-Later F, Malcus C, et al. Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients. Int Immunopharmacol. 2011;11(12):2086–90. https://doi.org/10.1016/j.intimp.2011.08.024.

108. Veterans Administration Systemic Sepsis Cooperative Study, G. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987;317(11):659–65. https://doi.org/10.1056/NEJM198709103171102.

109. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9. https://doi.org/10.1001/jama.2009.1754.

110. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991;325(2):81–6. https://doi.org/10.1056/NEJM199107113250202.

111. Werdan K. Immunoglobulin treatment in sepsis – is the answer “no”? Crit Care Med. 2006;34(5):1542–4. https://doi.org/10.1097/01.CCM.0000216189.80613.BB.

112. Werdan K. Mirror, mirror on the wall, which is the fairest meta-analysis of all? Crit Care Med. 2007;35(12):2852–4. https://doi.org/10.1097/01.CCM.0000297164.40980.F0.

113. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBPTS study. Crit Care Med. 2007;35(12):2693–701.

114. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for prevention of recurrent clostridium difficile infection. N Engl J Med. 2017;376(4):305–17. https://doi.org/10.1056/NEJMoa1602615.

115. Winau F, Winau R. Emil von Behring and serum therapy. Microbes Infect. 2002;4(2):185–8.

116. Winston DJ, Ho WG, Bartoni K, Champlin RE. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant. 1993;12(3):283–8.

117. Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med. 1987;106(1):12–8.

118. Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med. 1993;118(12):937–42.

119. Yap PL. Does intravenous immune globulin have a role in HIV-infected patients? Clin Exp Immunol. 1994;97(Suppl 1):59–67.

120. Stiehm EM, Keller MA. Passive immunization. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, et al., editors. Textbook of pediatric infectious diseases. 6th ed. Philadelphia: Saunders/Elsevier; 2009. p. 3412–47.